KR102186116B1 - 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법 - Google Patents

치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법 Download PDF

Info

Publication number
KR102186116B1
KR102186116B1 KR1020157014525A KR20157014525A KR102186116B1 KR 102186116 B1 KR102186116 B1 KR 102186116B1 KR 1020157014525 A KR1020157014525 A KR 1020157014525A KR 20157014525 A KR20157014525 A KR 20157014525A KR 102186116 B1 KR102186116 B1 KR 102186116B1
Authority
KR
South Korea
Prior art keywords
solution
vincristine
mol
liposome
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157014525A
Other languages
English (en)
Korean (ko)
Other versions
KR20150108350A (ko
Inventor
윌리암 티. 몬트
크리스토퍼 제임스 바보사
토마스 필립 웨버
Original Assignee
스펙트럼 파마슈티컬즈 인크
아뷰터스 바이오파마 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스펙트럼 파마슈티컬즈 인크, 아뷰터스 바이오파마 코포레이션 filed Critical 스펙트럼 파마슈티컬즈 인크
Priority to KR1020207034162A priority Critical patent/KR102310697B1/ko
Publication of KR20150108350A publication Critical patent/KR20150108350A/ko
Application granted granted Critical
Publication of KR102186116B1 publication Critical patent/KR102186116B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020157014525A 2012-11-20 2013-11-20 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법 Expired - Fee Related KR102186116B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207034162A KR102310697B1 (ko) 2012-11-20 2013-11-20 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728378P 2012-11-20 2012-11-20
US61/728,378 2012-11-20
PCT/US2013/071096 WO2014081887A1 (en) 2012-11-20 2013-11-20 Improved method for the preparation of liposome encapsulated vincristine for therapeutic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207034162A Division KR102310697B1 (ko) 2012-11-20 2013-11-20 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법

Publications (2)

Publication Number Publication Date
KR20150108350A KR20150108350A (ko) 2015-09-25
KR102186116B1 true KR102186116B1 (ko) 2020-12-03

Family

ID=49885379

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157014525A Expired - Fee Related KR102186116B1 (ko) 2012-11-20 2013-11-20 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
KR1020207034162A Active KR102310697B1 (ko) 2012-11-20 2013-11-20 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207034162A Active KR102310697B1 (ko) 2012-11-20 2013-11-20 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법

Country Status (14)

Country Link
US (1) US9801874B2 (enExample)
EP (2) EP2922529B1 (enExample)
JP (1) JP6419710B2 (enExample)
KR (2) KR102186116B1 (enExample)
CN (1) CN104837483B (enExample)
AU (1) AU2013347990B2 (enExample)
CA (1) CA2891656C (enExample)
ES (1) ES2730405T3 (enExample)
IL (1) IL238555B (enExample)
IN (1) IN2015DN04310A (enExample)
MX (1) MX2015005992A (enExample)
RU (1) RU2655964C2 (enExample)
TR (1) TR201908531T4 (enExample)
WO (1) WO2014081887A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN04310A (enExample) 2012-11-20 2015-10-16 Spectrum Pharmaceuticals
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CN108883069B (zh) * 2016-01-04 2021-07-20 中央研究院 基于酯化/皂化的用于微脂体负载的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059473A1 (en) 1999-04-01 2000-10-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2932718A (en) * 1957-06-25 1960-04-12 Thomas D Kinney Test tube warmer
US3115861A (en) 1960-02-29 1963-12-31 J L Tremper Locating elements of construction beneath the surface of earth soils
US3581703A (en) 1969-04-28 1971-06-01 Robert C Hosack Warning tape for underground installations
US3718113A (en) 1970-07-13 1973-02-27 Minnesota Mining & Mfg Buried pipeline signal
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
CA1260393A (en) 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US5622713A (en) 1985-09-17 1997-04-22 The Regents Of The University Of California Method of detoxifying animal suffering from overdose
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5755788A (en) 1987-02-19 1998-05-26 Rutgers, The State University Prosthesis and implants having liposomes bound thereto and methods of preparation
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
US5262168A (en) 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
US4952408A (en) 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
EP0472639A4 (en) 1989-05-15 1992-07-01 The Liposome Company, Inc. Accumulation of drugs into liposomes by a proton gradient
AU6428890A (en) 1989-09-12 1991-04-18 Regents Of The University Of California, The Therapeutic peptides and proteins
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
DE69329073T2 (de) 1992-03-23 2001-01-18 Georgetown University, Washington In liposomen verkapseltes taxol und verwendungsverfahren
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
GB9304745D0 (en) 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
EP0721328A4 (en) 1993-09-27 1997-09-17 Smithkline Beecham Corp CAMPTOTHECIN FORMULATIONS
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
IL115099A (en) 1994-10-14 1999-04-11 Upjohn Co Lyophilizate of phospholipid complex of water insoluble camptothecins
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
ATE285477T1 (de) 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998017256A1 (en) 1996-10-22 1998-04-30 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
BR9713661A (pt) 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
US6740335B1 (en) 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
BR9812316A (pt) 1997-09-16 2001-03-20 Nexstar Pharmaceuticals Inc Formulações de camptotecina lipossÈmica
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
DE69907243T2 (de) 1998-09-16 2004-02-19 Alza Corp., Mountain View In liposomen eingeschlossene topoisomerase inhibitoren
US5991013A (en) 1998-10-27 1999-11-23 At&T Corp. Conveyance warning member with sacrificial fiber
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7244450B2 (en) 1999-04-01 2007-07-17 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
EP1114839A4 (en) 1999-05-20 2002-09-25 Daicel Chem POLYESTER DIOL, POLYURETHANE OBTAINED FROM SAID DIOL AND SPANDEX FILAMENT THEREOF, AND NEW ACRYLIC COPOLYMER CONTAINING DIALKYLAMINO, POLYESTER COMPOSITION AND SPANDEX COMPOSITION
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US7094423B1 (en) 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6191119B1 (en) 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
WO2002002077A2 (en) 2000-06-30 2002-01-10 Inex Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
BR0114713A (pt) 2000-10-16 2004-01-13 Neopharm Inc Formulação lipossÈmica de mitoxantrona
US6825206B1 (en) 2000-11-16 2004-11-30 Research Triangle Institute Camptothecin compounds with a thioether group
EP1349917B1 (en) * 2000-12-08 2010-03-10 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
AU2002331481B2 (en) 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
ES2387886T3 (es) 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
US6627614B1 (en) 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
JP4245384B2 (ja) 2003-03-18 2009-03-25 株式会社ヤクルト本社 カンプトテシン類含有医薬組成物
JP2007522085A (ja) 2003-06-27 2007-08-09 スミスクライン・ビーチャム・コーポレイション 安定化されたトポテカンリポソーム組成物および方法
US20050129750A1 (en) 2003-12-15 2005-06-16 Yu-Fang Hu Process for producing liposome suspension and product containing liposome suspension produced thereby
UA86063C2 (ru) 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
DE602005018043D1 (de) 2004-05-17 2010-01-14 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
US7449196B2 (en) 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
CA2576222C (en) 2004-08-10 2014-09-30 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
JP4990786B2 (ja) 2004-11-05 2012-08-01 イネックス ファーマシューティカルズ コーポレイション 薬物リポソーム製剤を安定化するための組成物および方法
CN100356920C (zh) * 2004-12-27 2007-12-26 北京文卓医药生物制品技术开发有限公司 一种长春花属生物碱脂质体及其生产工艺
KR100793819B1 (ko) * 2006-06-16 2008-01-10 주식회사 펩트론 히트 블록 어셈블리 및 그를 이용한 유기 화합물 합성 반응장치
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2009059449A1 (en) * 2007-11-05 2009-05-14 Celsion Corporation Novel thermosensitive liposomes containing therapeutic agents
US8563907B2 (en) * 2008-02-26 2013-10-22 Mallinckrodt Llc Radiopharmaceutical heater
AU2012240030A1 (en) * 2011-04-05 2013-10-24 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of TRA kinase
IN2015DN04310A (enExample) 2012-11-20 2015-10-16 Spectrum Pharmaceuticals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059473A1 (en) 1999-04-01 2000-10-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma

Also Published As

Publication number Publication date
JP6419710B2 (ja) 2018-11-07
EP2922529A1 (en) 2015-09-30
TR201908531T4 (tr) 2019-08-21
AU2013347990B2 (en) 2018-01-18
ES2730405T3 (es) 2019-11-11
KR20150108350A (ko) 2015-09-25
EP2922529B1 (en) 2019-03-13
JP2016500077A (ja) 2016-01-07
US20150290184A1 (en) 2015-10-15
CA2891656C (en) 2021-05-04
CN104837483B (zh) 2017-09-01
US9801874B2 (en) 2017-10-31
EP3470061A1 (en) 2019-04-17
IL238555B (en) 2019-05-30
IL238555A0 (en) 2015-06-30
KR102310697B1 (ko) 2021-10-12
WO2014081887A1 (en) 2014-05-30
RU2655964C2 (ru) 2018-05-30
MX2015005992A (es) 2016-03-07
CA2891656A1 (en) 2014-05-30
CN104837483A (zh) 2015-08-12
IN2015DN04310A (enExample) 2015-10-16
AU2013347990A1 (en) 2015-05-21
RU2015117412A (ru) 2017-01-10
KR20200136060A (ko) 2020-12-04

Similar Documents

Publication Publication Date Title
Silverman et al. In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site
JP6941606B2 (ja) 安定化カンプトテシン医薬組成物
JP7041676B2 (ja) ガンの処置において使用するためのリポソーム製剤
JP2006513984A (ja) 医薬的に活性な、脂質をベースにしたｓｎ３８製剤
US20240173257A1 (en) Liposome formulations
JP2018533628A (ja) エキノマイシン製剤、その製造法および使用法
ES2952680T3 (es) Eribulina para inhibir el crecimiento tumoral
KR102186116B1 (ko) 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
US12447163B2 (en) Liposomal formulations of Bcl inhibitors
HK40007734A (en) Improved method for the preparation of a dosage of liposome encapsulated vincristine for therapeutic use
EP4370098A1 (en) Liposomal formulations of bcl inhibitors
HK40009643B (en) Liposomal formulation for use in the treatment of cancer
HK40009643A (en) Liposomal formulation for use in the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20231128

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231128